Patents by Inventor Regine Sitruk-Ware
Regine Sitruk-Ware has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190008763Abstract: The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects.Type: ApplicationFiled: September 7, 2018Publication date: January 10, 2019Inventors: Andre ULMANN, Erin GAINER, Delphine LEVY, Christine Seguin, Florian Battung, Regine SITRUK-WARE
-
Patent number: 10052335Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.Type: GrantFiled: October 19, 2010Date of Patent: August 21, 2018Assignee: The Population Council, Inc.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
-
Patent number: 9682087Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.Type: GrantFiled: December 17, 2010Date of Patent: June 20, 2017Assignees: The Population Council, Inc., Antares Pharma IPL AGInventors: Regine Sitruk-Ware, Dario Norberto Ramon Carrara, Arnaud Grenier
-
Patent number: 9446051Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration, and include effects on stroke and TBI.Type: GrantFiled: December 21, 2012Date of Patent: September 20, 2016Assignee: The Population Council, Inc.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
-
Patent number: 9364488Abstract: Methods for effective remyelination in patients are disclosed comprising treating the patient with an androgen receptor ligand which exerts binding to androgen receptors and elicits androgen-receptor-induced biological responses at a dosage sufficient to induce remyelination. The androgen compound preferably comprises MENT in an androgen targeting both androgen and estrogen receptors, and the methods include combining the androgen compound with a progestin compound in order to provide both contraception in men and treatment for neurodegeneration.Type: GrantFiled: March 22, 2012Date of Patent: June 14, 2016Assignee: The Population Council, Inc.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Abdelmouman Ghoumari, Said Ghandour, Rashad Hussain, Bartosz Bielecki
-
Publication number: 20150320766Abstract: The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects.Type: ApplicationFiled: December 13, 2013Publication date: November 12, 2015Inventors: André ULMANN, Erin GAINER, Delphine LEVY, Christine SEGUIN, Florian BATTUNG, Regine SITRUK-WARE
-
Patent number: 8865200Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.Type: GrantFiled: July 8, 2005Date of Patent: October 21, 2014Assignee: Laboratoire HRA PharmaInventors: Regine Sitruk-Ware, Yun-Yen Tsong
-
Publication number: 20140011791Abstract: Methods for effective remyelination in patients are disclosed comprising treating the patient with an androgen receptor ligand which exerts binding to androgen receptors and elicits androgen-receptor-induced biological responses at a dosage sufficient to induce remyelination. The androgen compound preferably comprises MENT in an androgen targeting both androgen and estrogen receptors, and the methods include combining the androgen compound with a progestin compound in order to provide both contraception in men and treatment for neurodegeneration.Type: ApplicationFiled: March 22, 2012Publication date: January 9, 2014Applicant: THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Abdelmouman Ghoumari, Said Ghandour, Rashad Hussain, Bartosz Bielecki
-
Publication number: 20130045953Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.Type: ApplicationFiled: December 17, 2010Publication date: February 21, 2013Applicants: ANTARES PHARMA IPL AG, THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Dario Norberto Ramon Carrara, Arnaud Grenier
-
Publication number: 20120231052Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.Type: ApplicationFiled: October 19, 2010Publication date: September 13, 2012Applicant: THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
-
Patent number: 8173593Abstract: Disclosed are methods and compositions containing endothelin receptor antagonists for emergency contraception.Type: GrantFiled: July 19, 2006Date of Patent: May 8, 2012Assignee: The Population Council, Inc.Inventors: Indrani C. Bagchi, Regine Sitruk-Ware
-
Publication number: 20090203591Abstract: Disclosed are methods and compositions containing endothelin receptor antagonists for emergency contraception.Type: ApplicationFiled: July 19, 2006Publication date: August 13, 2009Applicant: The Population Council, Inc.Inventors: Indrani C. Bagchi, Regine Sitruk-Ware
-
Publication number: 20080199511Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.Type: ApplicationFiled: July 8, 2005Publication date: August 21, 2008Applicant: Laboratoire HRA PharmaInventors: Regine Sitruk-Ware, Yun-Yen Tsong